<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297814</url>
  </required_header>
  <id_info>
    <org_study_id>PAD2UJCTC</org_study_id>
    <nct_id>NCT03297814</nct_id>
  </id_info>
  <brief_title>Use of Allogenic Platelet Lysate in Peripheral Arterial Disease (PAD)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled Trial, Investigating the Effect of Intramuscular Injection of Allogenic Platelet Lysate for the Treatment of PAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophia Al-Adwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogenic platelet lysate will be injected in the gastrocnemius of patients with peripheral
      arterial disease (PAD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogenic platelet rich plasma (PRP) will be collected from blood group AB donors. This
      plasma will be tested for the presence of any chronic infectious blood borne disease.

      Platelet lysate will be then prepared from the tested PRP to be intramuscularly injected in
      patients with PAD
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency and nature of adverse events occurring during a 6-month period following platelet lysate injection(s). This will be assessed by physical examination combined with a report with chemistry blood tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the preliminary efficacy of the platelet lysate injection on patients' ABI</measure>
    <time_frame>12 months</time_frame>
    <description>Positive changes in patients' Ankle brachial index (ABI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the preliminary efficacy of the platelet lysate injection on patients' Toe pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Positive changes in patients' Toe pressure (mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the preliminary efficacy of the platelet lysate injection on patients' TcPO2</measure>
    <time_frame>12 months</time_frame>
    <description>Positive changes in patients' Transcutaneous oxygen pressure (TcPO2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Platelet lysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet lysate</intervention_name>
    <description>Intramuscular injection of platelet lysate</description>
    <arm_group_label>Platelet lysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intramuscular injection of normal saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Competent and willing to give informed consent, and to be available for all baseline
             treatment and follow up examinations required by the protocol.

          -  Gender: Male or female.

          -  Age group &gt; 50 years.

          -  Established Critical limb ischemia (CLI), clinically and hemodynamically confirmed as
             per Rutherford 3, 4 and 5 with angiographic evidence of significant infra-inguinal
             arterial occlusive disease.

          -  History of intermittent claudication for &gt; eight weeks.

          -  Limited exercise due to moderate to severe claudication.

          -  Resting ABI &lt; 0.6, toe pressure ≤ 60 mm Hg, Toe Brachial index (TBI) &lt;0.6, or TcPO2 ≤
             60 mmHg in the foot.

          -  Not eligible for surgical or radiological revascularization, and doesn't respond to
             best standard care delivered as confirmed by a vascular surgeon and/or physician.

          -  Fairly controlled diabetes (Hemoglobin A1c &lt;10%).

          -  Normal liver enzymes, serum creatinine &lt; 1.4

          -  Normal platelet count.

          -  On regular medication for hypertension if any.

          -  No evidence of malignancy

          -  Body mass index &lt;30.

        Exclusion Criteria:

          -  Women with child bearing potential, pregnant and lactating women.

          -  Rheumatoid Arthritis.

          -  History of neoplasm or malignancy in the past 10 years.

          -  Reported unstable cardiovascular disease, heart failure or symptomatic postural
             hypotension within 6 months before screening.

          -  Leg edema

          -  Inflammatory or progressive fibrotic disorder

          -  Renal insufficiency or failure

          -  History of infectious disorder (Human immunodeficiency virus (HIV) and/or hepatitis
             viruses).

          -  Chronic inflammatory disease

          -  History of stroke or myocardial infarction (&lt; 3 months).

          -  Bleeding or clotting disorder, use of oral anticoagulant therapy (heparin, warfarin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdalla Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sofia Adwan, Msc</last_name>
    <phone>00962796175617</phone>
    <email>sophia.adwan@gmail.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Sophia Al-Adwan</investigator_full_name>
    <investigator_title>Clinical Co-ordinator</investigator_title>
  </responsible_party>
  <keyword>Peripheral arterial disease</keyword>
  <keyword>Platelet lysate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

